 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| 12345678910111213...1516» |
- | latanoprost / Generic mfg., Lumigan (bimatoprost) / Senju, AbbVie, travoprost ophthalmic / Generic mfg.
Journal: Predictors of severity in prostaglandin-associated periorbitopathy. (Pubmed Central) - Mar 9, 2025
Older age, longer duration of PGA therapy, and the use of bimatoprost and travoprost were significant and independent predictors of severe PAP in patients with glaucoma. Patients with these risk factors should be identified and managed to prevent the development of severe PAP.
- | Glanatec (ripasudil) / Kowa, Rhopressa (netarsudil) / Alcon
Journal: Drug- and Cell-Type-Specific Effects of ROCK Inhibitors as a Potential Cause of Reticular Corneal Epithelial Edema. (Pubmed Central) - Feb 25, 2025
Patients with these risk factors should be identified and managed to prevent the development of severe PAP. To explain the potential mechanisms, we comparatively analyzed the effects of ripasudil and netarsudil on corneal endothelial and epithelial function in vitro...Reticular bullous corneal epithelial edema was observed in a patient following netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (Roclanda
- | latanoprost / Generic mfg.
Journal: Lipidomic Analysis Reveals Drug-Induced Lipoxins in Glaucoma Treatment. (Pubmed Central) - Feb 20, 2025
In concert, an autocrine prostaglandin circuit mediates rapid IOP-lowering. This work reveals parallel mechanisms underlying acute and long-term latanoprost activities during the treatment of glaucoma.
- | latanoprost / Generic mfg.
Journal: Disclosing long-term tolerance, efficacy and penetration properties of hyaluronic acid-coated latanoprost-loaded liposomes as chronic glaucoma therapy. (Pubmed Central) - Feb 16, 2025
A daily topical application of LAT-HA-LIP for 15 consecutive days, effectively lowered IOP in a sustained way (2.51-3.88?mmHg mean IOP reduction over the 5-15-day period). These results highlight the clinical relevance of the proposed technological platform, able to provide IOP reduction during the simulated long-term administration and simultaneous ocular surface protection with potential for the treatment of glaucoma.
- | latanoprost / Generic mfg.
Journal: Development of a conjunctival contact-type drug delivery device for latanoprost using hyaluronic acid. (Pubmed Central) - Feb 4, 2025
Overall, HA-latanoprost effectively lowered IOP and reduced ocular irritation more than latanoprost eyedrops in mice. However, these results are based on animal testing, so further development is needed for clinical use.
- || latanoprost / Generic mfg., Rhopressa (netarsudil) / Alcon
Retrospective data, Review, Journal: Comparative Efficacy and Safety of Netarsudil-Containing Interventions for Intraocular Pressure Control: A Systematic Review and Network Meta-Analysis. (Pubmed Central) - Feb 4, 2025
Both FDCs achieved substantial reductions in IOP and a high proportion of patients reaching target IOPs. However, safety profiles indicate that traditional therapies like latanoprost 0.005% and timolol 0.5% may have fewer side effects, including lower incidences of blurred vision, conjunctival hemorrhage, and conjunctival hyperemia.
- || Rescula (unoprostone isopropyl) / Santen, Mallinckrodt
Retrospective data, Review, Journal: Comparative analysis of medical treatments for long-term control of normal tension glaucoma: A systematic review and model-based network meta-analysis. (Pubmed Central) - Feb 3, 2025
This study revealed PEA as a promising agent for long-term IOP control in NTG patients, suggesting potential use as primary or adjunctive therapy. The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long-term efficacy and safety for NTG.
- | latanoprost / Generic mfg.
Journal, HEOR: Economic impact of initial glaucoma treatment with selective laser trabeculoplasty on the Brazilian Public Health System. (Pubmed Central) - Jan 29, 2025
The outcomes call for PEA's consideration in clinical practice and highlight the need for further research into its long-term efficacy and safety for NTG. As the initial treatment for primary open-angle glaucoma, selective laser trabeculoplasty exhibited a lower economic impact on SUS than latanoprost and timolol maleate eye drop instillation in all the studied scenarios over one and five-year periods.
- | latanoprost / Generic mfg., dorzolamide/timolol / Generic mfg.
Journal: Polydipsia Induced Acute Angle-Closure Crisis. (Pubmed Central) - Jan 28, 2025
He started topical brimonidine, dorzolamide 2%/timolol 0.5%, and latanoprost, and underwent phacoemulsification with placement of a posterior chamber intraocular lens (PCIOL) in the right eye. Several mechanisms of polydipsia induced AACC are proposed including choroidal expansion, increased sympathetic ?-adrenergic tone, or differences in osmotic potential forces.
- | latanoprost / Generic mfg., dorzolamide / Generic mfg.
Journal: Allergic Contact Dermatitis to Both Latanoprost and Dorzolamide in Eye Drops. (Pubmed Central) - Jan 28, 2025
Several mechanisms of polydipsia induced AACC are proposed including choroidal expansion, increased sympathetic ?-adrenergic tone, or differences in osmotic potential forces. No abstract available
- || Rocklatan (latanoprost/netarsudil) / Alcon
Clinical, P4 data, Journal: Effects of Switching to Netarsudil/Latanoprost Fixed Dose Combination from Various Latanoprost Regimens: The Phase 4 MORE Study. (Pubmed Central) - Jan 27, 2025
In this study, additional IOP lowering was achievable when patients switched to netarsudil/latanoprost FDC after treatment with latanoprost alone or latanoprost with 1 or 2 additional agents. The once-daily administration of netarsudil/latanoprost FDC and reduced treatment burden for those on latanoprost combined with additional agents may prove more manageable for patients.
- || latanoprost / Generic mfg., Lumigan (bimatoprost) / Senju, AbbVie
Clinical, Journal: Evaluation of the efficacy, safety, and satisfaction rate of topical latanoprost in patients with hypopigmented burn scars treated with fractional CO2 laser: a double-blind randomized controlled clinical trial. (Pubmed Central) - Jan 12, 2025
The combination of CO2 fractional laser and latanoprost was significantly more effective than CO2 fractional laser alone based on the SGAIS criteria, as evaluated by physicians and patients in all three follow-up sessions. Additionally, the satisfaction of the patients in the combined treatment group was significantly higher than that of the CO2 fractional laser treatment group.
- ||||| bimatoprost grenod (NCX 470) / Nicox
Enrollment closed, Trial primary completion date: Denali: MRCT Evaluating NCX 470 vs. Latanoprost in Subjects With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - Jan 9, 2025
P3, N=696, Active, not recruiting, Sponsor: Nicox Ophthalmics, Inc.
Additionally, the satisfaction of the patients in the combined treatment group was significantly higher than that of the CO2 fractional laser treatment group. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Mar 2025
- | latanoprost / Generic mfg.
Preclinical, Journal: The Optejet Technology Minimizes Preservative-Mediated Cytotoxicity of Conjunctival Epithelial Cells Treated with Latanoprost In Vitro. (Pubmed Central) - Dec 6, 2024
A microdose of latanoprost+BAK ophthalmical spray administered with the Optejet technology prevented the cytotoxicity associated with larger volumes found in eye drops. Precision dosing by the Optejet technology has the potential to decrease ocular surface disorder typically associated with eye drops containing preservatives.
- | latanoprost / Generic mfg.
Preclinical, Journal: In vitro tear replenishment system: assessing drug delivery from contact lens biomaterials through corneal epithelial monolayer and multilayer under replenishment conditions. (Pubmed Central) - Dec 5, 2024
The apical release of latanoprost was significantly lower under replenishment compared to no-replenishment conditions. These results demonstrate the role that a dynamic release model will have in predicting the amount of drug that can be released from a contact lens into the tear film and the critical role of a cell monolayer in in vitro drug delivery studies.
- | Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Journal: Changes in prostaglandin-associated periorbital syndrome: a self-controlled and prospective study. (Pubmed Central) - Dec 2, 2024
P4
Bimatoprost caused the most severe PAPS, and latanoprost caused the least severe PAPS. The study was registered at www.chictr.org.cn on 15 April 2021, under the identifier ChiCTR2100045465.
- || latanoprost / Generic mfg., travoprost ophthalmic / Generic mfg.
P2 data, Journal: Efficacy and Safety of a Preservative-Free Latanoprost Cationic Emulsion in Patients with Open-Angle Glaucoma and Concurrent Ocular Surface Disease: A Randomized Phase 2 Study. (Pubmed Central) - Nov 16, 2024
PF-latanoprost-E effectively and safely lowered IOP and improved OSD parameters in patients with OAG/OH. These findings provide evidence for the beneficial effects of this new formulation of latanoprost in glaucoma patients with OSD.
- | latanoprost / Generic mfg.
Journal: Self-assembled latanoprost loaded soluplus nanomicelles as an ophthalmic drug delivery system for the management of glaucoma. (Pubmed Central) - Nov 15, 2024
These findings provide evidence for the beneficial effects of this new formulation of latanoprost in glaucoma patients with OSD. In normotensive rabbits, the nanomicelles elicited a substantial reduction in intraocular pressure (IOP) by up to 40% for a duration of three days, that was significantly longer than the IOP-lowering efficacy of XALATAN eye drops (24
- |||||||||| latanoprost / Generic mfg.
New P3 trial: A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China (clinicaltrials.gov) - Oct 31, 2024
P3, N=338, Not yet recruiting, Sponsor: Santen Pharmaceutical Co., Ltd.
- | latanoprost / Generic mfg., timolol maleate ophthalmic solution / Generic mfg.
Trial completion date, Trial primary completion date: Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (clinicaltrials.gov) - Oct 29, 2024
P4, N=100, Recruiting, Sponsor: Ohio State University
In normotensive rabbits, the nanomicelles elicited a substantial reduction in intraocular pressure (IOP) by up to 40% for a duration of three days, that was significantly longer than the IOP-lowering efficacy of XALATAN eye drops (24 Trial completion date: May 2025 --> Aug 2025 | Trial primary completion date: Dec 2024 --> May 2025
- | latanoprost / Generic mfg.
Journal: The effects of topical latanoprost 0.005% treatment on microvascular changes in the optic nerve head and macula. (Pubmed Central) - Oct 25, 2024
The initial increase in ONH and peripapillary VD, as well as macular VD, is attributed to the acute reduction in IOP from topical latanoprost 0.005%. However, the diminishment of sustained differences by the 3rd month indicates adaptation of the ONH and retinal microvasculature to decreased IOP through compensatory mechanisms.
- ||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Journal, Adverse events: Adverse events of topical ocular prostaglandin medications for glaucoma treatment: a pharmacovigilance study based on the FAERS database. (Pubmed Central) - Oct 21, 2024
Although signal detection analysis based on the FAERS database cannot establish a definitive causal relationship, our study found that FP receptor agonists used in glaucoma can cause various adverse events. Assessing their clinical suitability and potential side effects is crucial for providing personalized treatment and ensuring medication safety.
- | Lumigan (bimatoprost) / Senju, AbbVie
Journal: Evaluation of the Effect of Topical Prostaglandin Analog Treatment on Orbital Structures in Open-Angle Glaucoma with Computed Tomography. (Pubmed Central) - Oct 16, 2024
ICC values demonstrated excellent reliability (ICC > 0.75) for all measurements. We did not find significant differences in enophthalmos measurements, orbital fat volume, total muscle volume, and optic nerve volume between the PGA-treated and untreated eyes.
- | Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - Oct 10, 2024
P3, N=500, Completed, Sponsor: University of Miami
We did not find significant differences in enophthalmos measurements, orbital fat volume, total muscle volume, and optic nerve volume between the PGA-treated and untreated eyes. Active, not recruiting --> Completed | Trial completion date: Jul 2025 --> Oct 2024 | Trial primary completion date: Jul 2025 --> Oct 2024
- || latanoprost / Generic mfg., cyclosporin A microemulsion / Generic mfg., timolol maleate ophthalmic solution / Generic mfg.
Review, Journal: Elucidating acceptance and clinical indications to support the rational design of drug-eluting contact lenses. (Pubmed Central) - Oct 9, 2024
It is hoped that this review will facilitate a deeper understanding of DECLs acceptance and indications, thereby supporting the rational design of DECLs. At the same time, this review provides a reference for the design of other drug-device combination products.
- | latanoprost / Generic mfg.
New P1 trial: Effect of Latanoprost on Optic Nerve Perfusion (clinicaltrials.gov) - Oct 7, 2024
P1, N=46, Completed, Sponsor: Zagazig University
- | Zioptan (tafluprost) / Santen, Merck (MSD)
Journal: Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension - an observer blinded active-control trial. (Pubmed Central) - Oct 3, 2024
At the same time, this review provides a reference for the design of other drug-device combination products. Preservative-free and benzalkonium chloride-containing drops were found to be equally effective in lowering IOP with no significant difference in either subjective or objective measurements of dry eye severity.
- | latanoprost / Generic mfg., dexamethasone injection / Generic mfg.
Preclinical, Journal: Subconjunctival Administration of an Adeno-Associated Virus Expressing Stanniocalcin-1 Provides Sustained Intraocular Pressure Reduction in Mice. (Pubmed Central) - Sep 27, 2024
Preservative-free and benzalkonium chloride-containing drops were found to be equally effective in lowering IOP with no significant difference in either subjective or objective measurements of dry eye severity. Steroid-mediated ocular hypertension was induced in C57BL/6J mice with weekly injections of dexamethasone into the conjunctival fornix, and mice were then injected subconjunctivally with 6
- latanoprost / Generic mfg.
Cardiovascular Effects of Topical Glaucoma Medications in U.S. Adults (DEMAND) - Sep 24, 2024 - Abstract #AAO2024AAO_2134;
Methods This within-subjects cohort study identified subjects with a glaucoma diagnosis over age 40 prescribed topical timolol, brimonidine or latanoprost as first-line IOP-lowering therapies from the All of Us dataset (ver...After initiating brimonidine, subjects had a lower HR (76.7 BPM before versus 75.3 after; P < .001) and DBP (76.8 before versus 76.0 after; P = .002), but not SBP. Conclusion Glaucoma medications minimally affect cardiovascular parameters.
- latanoprost / Generic mfg., timolol maleate ophthalmic solution / Generic mfg.
Safety and Efficacy of IOP-Lowering Microdrops Administered With the Nanodropper Adaptor in Glaucoma and OHT Patients (South Level 1 Lobby: STATION 2) - Sep 24, 2024 - Abstract #AAO2024AAO_1404;
MD decreased AE prevalence by 65.3% compared to CD. Conclusion MD improved IOP-lowering efficacy and decreased prevalence of PBE and AEs compared to CD in this cohort of OAG/OHT patients.
- |||| latanoprost / Generic mfg.
Enrollment open: EVOLVE: A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Pseudophakic Eyes (clinicaltrials.gov) - Sep 4, 2024
P4, N=334, Recruiting, Sponsor: Sight Sciences, Inc.
Conclusion MD improved IOP-lowering efficacy and decreased prevalence of PBE and AEs compared to CD in this cohort of OAG/OHT patients. Not yet recruiting --> Recruiting
- ||| Lumigan (bimatoprost) / Senju, AbbVie, Zioptan (tafluprost) / Santen, Merck (MSD)
Journal, Adverse events: Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database. (Pubmed Central) - Sep 1, 2024
Not yet recruiting --> Recruiting Our findings have revealed a potential relationship due to the biological plausibility among malignant mediastinal neoplasm, full blood count abnormal, blood immunoglobulin E increased, diabetes mellitus, blepharospasm, cataracts, chest discomfort and dry mouth; therefore, it is relevant to continue investigating the possible drug-event association, whether to refute the safety signal or identify a new risk.
- | Combigan (brimonidine tartrate/timolol maleate) / AbbVie
Journal: Severe intraocular pressure rise after implantable collamer lens implantation. (Pubmed Central) - Aug 26, 2024
Prednisolone acetate 0.1% ophthalmic suspension eye drops and ofloxacin 0.3% ophthalmic solution eye drops 4 times daily were prescribed prophylactically 2 days preoperatively...The patient was instructed to reduce prednisolone to 2 times a day, discontinue brimonidine, and start brimonidine/timolol (Combigan) 2 times a day and latanoprost at bedtime in both eyes...The patient was instructed to reduce prednisolone to once a day, continue brimonidine/timolol 2 times a day and latanoprost at bedtime, and start acetazolamide (Diamox) 250 mg 2 times a day...What is the most likely mechanism underlying this patient's elevated IOP? What additional diagnostic workup would aid you in making the correct diagnosis?
- | latanoprost / Generic mfg.
Journal: Effect of latanoprost on choroidal thickness in patients with newly diagnosed primary open-angle glaucoma. (Pubmed Central) - Aug 21, 2024
Topical latanoprost may increase choroidal thickness. Swept Source-OCT may contribute to our understanding of the actions of latanoprost on choroidal thickness.
- | latanoprost / Generic mfg.
Journal: Evaluation of the lamina cribrosa after topical latanoprost therapy in primary open-angle glaucoma or ocular hypertension. (Pubmed Central) - Aug 19, 2024
POAG/OHT patients showed more LC thinning compared with healthy individuals. The significant increase in LC thickness and the significant decrease in LC depth were detected after IOP reduction therapy with latanoprost in ocular hypertensive/ glaucomatous eyes.
- || Eucrisa (crisaborole) / Pfizer, Lumigan (bimatoprost) / Senju, AbbVie, Cervidil (dinoprostone) / Ferring
Review, Journal: Utility of prostaglandin analogues and phosphodiesterase inhibitors as promising last resorts for the treatment of vitiligo: A systematic review, from mechanisms of action to mono-, combination and comparative therapies. (Pubmed Central) - Aug 19, 2024
The significant increase in LC thickness and the significant decrease in LC depth were detected after IOP reduction therapy with latanoprost in ocular hypertensive/ glaucomatous eyes. Monotherapy or add-on PGAs and PDEIs can be considered effective treatments for vitiligo and promising last resorts for those resistant to other therapies.
- | latanoprost / Generic mfg., timolol maleate ophthalmic solution / Generic mfg.
Trial completion date, Trial primary completion date: Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (clinicaltrials.gov) - Aug 18, 2024
P4, N=100, Recruiting, Sponsor: Ohio State University
Monotherapy or add-on PGAs and PDEIs can be considered effective treatments for vitiligo and promising last resorts for those resistant to other therapies. Trial completion date: Aug 2024 --> May 2025 | Trial primary completion date: Jul 2024 --> Dec 2024
- || latanoprost / Generic mfg.
Enrollment closed: Assess the Safety, Tolerability and Efficacy of Latanoprost Liposome for Lower Eyelid Steatoblepharon (clinicaltrials.gov) - Aug 12, 2024
P1, N=40, Active, not recruiting, Sponsor: Peregrine Ophthalmic
Trial completion date: Aug 2024 --> May 2025 | Trial primary completion date: Jul 2024 --> Dec 2024 Recruiting --> Active, not recruiting
- | latanoprost / Generic mfg.
Journal: Real-Life Study on the Efficacy and Tolerance of a Preservative-Free Surfactant-Free Latanoprost Eye Drop in Patients with Glaucoma. (Pubmed Central) - Aug 12, 2024
PFSF-LAT is an efficient treatment for patients with glaucoma with an improved tolerance profile. It can be considered as initial therapy in na
- latanoprost / Generic mfg.
Evaluation of the Efficacy, Safety, and Satisfaction Rate of Topical Latanoprost in Patients with Hypopigmented Burn Scars Treated with Fractional CO2 Laser: A Double-Blind Randomized Controlled Clinical Trial (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_5172;
Using topical latanoprost is a successful method for promoting repigmentation in hypopigmented and depigmented burn scar lesions. When this topical medication is combined with fractional CO2 laser treatment, it improves the laser
- ||| Omlonti (omidenepag isopropyl) / Santen, Ube Corp
Clinical, P3 data, Journal: Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial. (Pubmed Central) - Jul 26, 2024
P3
Most AEs were mild, with no serious ocular AEs. OMDI safely and effectively reduces IOP in Asian subjects with OAG/OHT, with mean diurnal IOP at Month 3 and per-timepoint IOP reductions non-inferior to those of latanoprost.
- | Lumigan (bimatoprost) / Senju, AbbVie, nitric oxide (NO)?donating bimatoprost analog (NCX 470) / Nicox
Journal: A Randomized, Controlled Comparison of NCX 470, a Nitric Oxide-Donating Bimatoprost, and Latanoprost in Subjects with Open-Angle Glaucoma or Ocular Hypertension: The MONT BLANC Study. (Pubmed Central) - Jul 18, 2024
The NO-donating prostaglandin analogue NCX 470 0.1% was well-tolerated and lowered IOP more than latanoprost in subjects with OAG or OHT at all 6 time points. With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma.
- | latanoprost / Generic mfg.
Journal: A Rare Case of Latanoprost-Induced Eyelash Poliosis. (Pubmed Central) - Jun 25, 2024
With a dual mechanism of action that enhances both uveoscleral and trabecular outflow, NCX 470 could become an important first-line therapy for IOP reduction in glaucoma. No abstract available
- | Lumigan (bimatoprost) / Senju, AbbVie, NN1213 / Novo Nordisk
Trial completion date, Trial primary completion date: STOP-RGCD: Stop Retinal Ganglion Cell Dysfunction Study (clinicaltrials.gov) - Jun 23, 2024
P3, N=500, Active, not recruiting, Sponsor: University of Miami
No abstract available Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- || minoxidil / Generic mfg.
Retrospective data, Review, Journal: Allergic Contact Dermatitis to Topical Preparations Containing Minoxidil: A Systematic Review and Individual Participant Data Meta-Analysis. (Pubmed Central) - Jun 17, 2024
The findings indicate that minoxidil is the predominant allergen in ACD reactions to its topical formulations, followed by propylene glycol. For the accurate diagnosis of ACD related to minoxidil, patch testing with 2% minoxidil in propylene glycol is recommended, as are separate tests for propylene glycol and other potential allergenic ingredients.
- |||| Rhopressa (netarsudil) / Alcon
New P4 trial: Effect of Netarsudil vs Brimonidine in NTG Patients on Latanoprost (clinicaltrials.gov) - Jun 10, 2024
P4, N=100, Recruiting, Sponsor: Westlake Eye Specialists
- ||||||| Catioprost (latanoprost emulsion) / Santen
Trial completion: A Phase III Multinational Multicenter Investigator-Masked Randomized Active-Controlled Trial Comparing the Efficacy and Safety of DE-130A With Xalatan (clinicaltrials.gov) - May 28, 2024
P3, N=386, Completed, Sponsor: Santen SAS
For the accurate diagnosis of ACD related to minoxidil, patch testing with 2% minoxidil in propylene glycol is recommended, as are separate tests for propylene glycol and other potential allergenic ingredients. Active, not recruiting --> Completed
- ||||| JV-GL1 / JeniVision
Trial completion date, Trial suspension, Trial primary completion date: Safety and Efficacy Study of JV-GL1 in Patients With Open-Angle Glaucoma or Ocular Hypertension (clinicaltrials.gov) - May 10, 2024
P1/2, N=70, Suspended, Sponsor: JeniVision, Inc.
Active, not recruiting --> Completed Trial completion date: Jul 2023 --> Jul 2025 | Active, not recruiting --> Suspended | Trial primary completion date: Mar 2023 --> Mar 2025
- ||||| latanoprost / Generic mfg.
New P4 trial: EVOLVE: A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Pseudophakic Eyes (clinicaltrials.gov) - May 9, 2024
P4, N=334, Not yet recruiting, Sponsor: Sight Sciences, Inc.
- | latanoprost / Generic mfg.
Preclinical, Journal: Retinal Neurodegeneration in an Intraocular Pressure Fluctuation Rat Model. (Pubmed Central) - Apr 17, 2024
Male rats were treated with IOP-lowering eyedrops (brinzolamide and latanoprost) on Mondays and Thursdays (in the irregular instillation group) or daily (in the regular instillation group), and saline was administered daily in the normal control group for 8 weeks...Expression of cleaved caspase-3 was upregulated and the number of retinal ganglion cells (RGCs) was decreased in the irregular instillation group. Our findings indicate that IOP fluctuations could be induced by irregular instillation of IOP-lowering eyedrops and this could lead to the degeneration of RGCs, probably through increased oxidative stress and macrogliosis.